论文部分内容阅读
据报道:法国研究人员对神经内分泌的结合点一咪唑啉受体的研究取得新进展。他们发现这种受体能特异性的无副作用的调节血压。法国一个公司已经生产出一种能优先与咪唑啉受体结合的降压新药瑞麦尼丁(Rilmenidine)。首先,研究者们在人的大脑、肾和其它部位发现了咪唑啉受体。他们确信,目前抗高血压药,例如可乐定、甲基多巴、利血平,它们大部份降压效果是通过与咪唑啉受体结合来实现的。而这些药公认的副作用,如精神抑郁、口干、反应迟钝、情绪不稳和记忆力减退,则是由于它们与α_2肾上腺素能受体结合造成的结果。法国研制出的这种降压新药瑞麦尼丁,其前身
It is reported that: French researchers made new progress on the neuroendocrine binding point of imidazoline receptor. They found that this receptor can specifically and without side effects regulate blood pressure. A French company has produced a new antihypertensive drug, Rilmenidine, that binds preferentially to imidazoline receptors. First, researchers found imidazolinium receptors in the human brain, kidneys and other areas. They are convinced that the current antihypertensive drugs, such as clonidine, methyldopa, reserpine, most of their antihypertensive effect is through the combination of imidazoline receptors. The recognized side effects of these drugs, such as depression, dry mouth, unresponsiveness, mood swings and memory loss, are attributed to their association with alpha 2 adrenergic receptors. The antihypertensive drug developed in France, Remy Martin, its predecessor